University of Cincinnati

Michael J Edwards

Erich Gulbins

Aaron Seitz

Ryan Gobble

Ronald C Watson

Andrew C Whitten

Matthew W Ales

Yuanming R Li

Alex B Lentsch

Jeffrey C Millman

Roy Mcgillivray

Iii Malloy John D

Scott J Shargots

Methods for applying a coating to a surface of a substrate for inhibition and prevention of implant-associated complications (including implant-associated infections), methods for inhibiting and preventing implant-associated complications (including implant-associated infections), implant-associated infection inhibiting coatings, and coated devices are provided. Coating processes include a) providing a saturated or supersaturated solution of an antibiotic in a fast-evaporating or medium-evaporating organic solvent; b) coating the surface of the substrate with at least one application of solution, each application followed directly by a solvent evaporation period.

Coated medical devices and methods of inhibiting implant-associated infections

Methods for applying a sphingolipid aggregate coating to a surface of a substrate for inhibition and prevention of biofilm growth, methods for inhibiting and preventing biofilms, biofilm-inhibiting coatings and coated devices are provided. Coating processes include suspending an amount of sphingolipid in a medium-to-fast-evaporating organic solvent; b) applying energy to the suspension sufficient to create a colloidal dispersion of sphingolipid in the solvent; c) heating the dispersion sufficient to create a solution; and d) coating the surface of the substrate with at least one application of solution, each application followed directly by a complete solvent evaporation period. The resulting coatings exhibit aggregate architectures particularly effective for inhibition and prevention of biofilms.

Sphingolipid coatings and process for manufacturing sphingolipid coatings effective for inhibiting biofilm formation

Antibiotic implant coatings and process for manufacturing implant coatings

A pharmaceutical composition containing (1) a therapeutically effective amount of hepatocyte-derived exosomes; and (2) a pharmaceutically-acceptable carrier is provided. Also provided herein is a method of inducing liver regeneration in a patient in need thereof, the method including administering to the patient a therapeutic amount of hepatocyte-derived exosomes, wherein liver regeneration is induced. Methods for up-regulating synthesis of synthesis of sphingosine-1-phosphate (S1P) in a hepatocyte by contacting the hepatocyte with at least one vesicle containing sphingosine kinase 2, and, optionally, ceramide and neutral ceramidase, are also disclosed.

Compositions and methods for inducing liver regeneration by administering hepatocyte-derived exosomes

Growing community of inventors

Cincinnati, OH, United States of America

Michael J Edwards